Compare Otis Worldwide Corp (OTIS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Zimmer Biomet Holdings Inc — how do they compare? Otis Worldwide Corp trades at $70.61 (market cap $27.61B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| OTIS | ZBH | |
|---|---|---|
Market Cap | $27.61B | $17.20B |
Sector | Industrials | Health |
52-Week High | $100.99 | $107.71 |
52-Week Low | $69.34 | $79.58 |
Enterprise Value | $34.99B | $24.25B |
Dividend Yield | 2.36% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $71.95, down 2.04% recently, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates but showing strong service growth. Revenue trends are stable, with 2025 revenue at $14.43B and net income of $1.38B. Analyst consensus is a Buy with a $91.00 price target, implying significant upside. Recent news highlights modernization initiatives and Q2 earnings focus.
The outlook for OTIS is cautiously optimistic, with potential driven by service segment strength and strategic upgrades, but risks include margin pressures from tariffs and economic headwinds. Valuation at a P/E of 19.54 is reasonable, yet debt levels and recent earnings misses warrant monitoring. Institutional sentiment is mixed, with 38% Buy ratings offset by high debt-to-asset ratio of 75.54% as of 2025.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
